Investigator: Ji Qiu, Ph.D., Garrick Wallstrom, Ph.D. and Shilpa Shivakumar, M.D.
Collaborators: William Rom, M.D. (New York University School of Medicine)
|Who gets it?
What are the symptoms?
|How do we detect it now?
How is it currently treated?
|What are the current challenges?|
Lung Cancer is the leading cause of cancer death in men and women. Current detection methods, such as CT scans often miss cancer cases or result in false positives that aren’t actually cancer. By combining CT scans and biomarkers in the blood that we plan to identify using our protein array technology, our goal is to develop tools to distinguish early lung cancer from benign lesions to spare unneeded surgeries and detect lunch cancer earlier and more accurately leading to better outcomes. We have completed the first step in identifying biomarkers for lung cancer. Blood samples from 40 lung cancer patients and 40 cancer-free individuals provided by New York University were screened on the 10,000 protein NAPPA array to identify potential autoantibody biomarkers of lung cancer. The next steps will including verifying the biomarkers using additional samples, comparing these lung cancer biomarkers to biomarkers from other disease controls, and correlating these biomarkers with disease diagnosis, outcome and results from lung CT scans.